BBIO

Over the past six months, BridgeBio Pharma's stock (BBIO) fell approximately 13.84% as of early October 2026, though it showed an 18.62% increase over the past year. In the 30 days leading up to early September 2026, shares declined by roughly 10.2% due to profit-taking, an oversubscribed secondary offering by KKR, and fading momentum. Despite this, the stock was up approximately 12.6% over the trailing quarter, reflecting a broader multi-month uptrend. For Q2 2026, reported on August 10, 2026, the company posted an EPS of -0.780 USD and revenue rose 120% year over year to $243.7 million, driven by Attruby. Q1 2026 earnings, reported on May 7, 2026, showed an EPS of -0.840 USD and total revenues of $194.5 million, with $180.6 million from U.S. Attruby net product revenue. Clinical and regulatory milestones include the presentation of new Phase 3 ATTRibute-CM data for acoramidis on August 30, 2026, an expected FDA decision on BBP-418 by November 27, 2026, a target FDA action date for encaleret of May 8, 2027, and the submission of a New Drug Application (NDA) for infigratinib in Q3 2026 with potential approval in mid-2027. In July 2026, the company secured $933.9 million through the sale of preferred stock to Sixth Street and HCRx.